Innovus Pharma Announces the Launch of Its Product AllerVarx in Canada for Allergic Rhinitis

Innovus Pharmaceuticals (OTCQB:INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today announced the launch of its product AllerVarx™, which is a clinically proven, Natural Health Product approved by Health Canada to help reduce symptoms of allergic rhinitis such as nasal discharge, sneezing, nasal congestion and itching. Innovus Pharma launched AllerVarx™ in Canada through the Company’s website and its Canadian Beyond Human™ marketing and sales platform.

As quoted in the press release:

“We are happy to announce the launch of AllerVarx™ in Canada,” said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. “We believe the product will sell well there for customers with allergic rhinitis and represents the fifth product launched through our own sales and marketing commercial efforts in Canada in addition to ProtaGoRx™, Vesele®, Apeaz® and Xyralid® and is our ninth product on the Canadian market including Zestra®, Zestra Glide® and Uxor™ (EjectDelay™) marketed by Orimed Pharma and UriVarx® through our partnership with Acerus Pharmaceuticals Corporation. We have been experiencing a much higher return on our ads in Canada and we expect the Canadian market to grow and become a more significant source of revenue for the Company,” continued Dr. Damaj.

Click here to read the full press release.